Works by Anguera, Georgia

Results: 18
    1

    Pilot Investigation on Markers of Bone Metabolism, Angiogenesis, and Neuroendocrine Activity as Potential Predictors of Survival of Metastatic Prostate Cancer Patients with Bone Metastases.

    Published in:
    International Journal of Molecular Sciences, 2025, v. 26, n. 10, p. 4669, doi. 10.3390/ijms26104669
    By:
    • Ortiz, Maria Angels;
    • Anguera, Georgia;
    • Cantó, Elisabet;
    • Alejandre, Jose;
    • Mora, Josefina;
    • Osuna-Gómez, Ruben;
    • Mulet, Maria;
    • Mora, Pradip;
    • Antonijuan, Assumpta;
    • Sánchez, Sofia;
    • Ramírez, Ona;
    • Orantes, Vanessa;
    • Maroto, Pablo;
    • Vidal, Silvia
    Publication type:
    Article
    2
    3

    Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib.

    Published in:
    Clinical Genitourinary Cancer, 2023, v. 21, n. 3, p. e166, doi. 10.1016/j.clgc.2022.11.021
    By:
    • de Velasco, Guillermo;
    • Alonso-Gordoa, Teresa;
    • Rodríguez-Vida, Alejo;
    • Anguera, Georgia;
    • Campayo, Marc;
    • Pinto, Álvaro;
    • Martínez Ortega, Esther;
    • Gallardo, Enrique;
    • Fernández Núñez, Natalia;
    • García-Carbonero, Iciar;
    • Reig, Oscar;
    • Méndez-Vidal, María José;
    • Fernández-Calvo, Ovidio;
    • Cassinello, Natalia Vidal;
    • Torregrosa, Dolores;
    • López-Martín, Ana;
    • Rosero, Adriana;
    • Valiente, Patricia G.;
    • Garcías de España, Carmen;
    • Climent, Miguel A.
    Publication type:
    Article
    4

    Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.

    Published in:
    Clinical Genitourinary Cancer, 2022, v. 20, n. 1, p. 25, doi. 10.1016/j.clgc.2021.09.006
    By:
    • Pinto, Álvaro;
    • Reig, Oscar;
    • Iglesias, Clara;
    • Gallardo, Enrique;
    • García-del Muro, Xavier;
    • Alonso, Teresa;
    • Anguera, Georgia;
    • Suárez, Cristina;
    • Muñoz-Langa, José;
    • Villalobos-León, Laura;
    • Rodríguez-Sánchez, Ángel;
    • Lainez, Nuria;
    • Martínez-Ortega, Esther;
    • Campayo, Marc;
    • Velastegui, Alejandro;
    • Rodriguez-Vida, Alejo;
    • Villa-Guzmán, José C.;
    • Méndez-Vidal, Maria J.;
    • Rubio, Gustavo;
    • García, Iciar
    Publication type:
    Article
    5

    Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.

    Published in:
    Cancer Immunology, Immunotherapy, 2023, v. 72, n. 11, p. 3665, doi. 10.1007/s00262-023-03518-z
    By:
    • Fiala, Ondřej;
    • Buti, Sebastiano;
    • Takeshita, Hideki;
    • Okada, Yohei;
    • Massari, Francesco;
    • Palacios, Georgia Anguera;
    • Dionese, Michele;
    • Scagliarini, Sarah;
    • Büttner, Thomas;
    • Fornarini, Giuseppe;
    • Myint, Zin W.;
    • Galli, Luca;
    • Souza, Vinicius Carrera;
    • Pichler, Renate;
    • De Giorgi, Ugo;
    • Quiroga, María Natalia Gandur;
    • Gilbert, Danielle;
    • Popovic, Lazar;
    • Grande, Enrique;
    • Mammone, Giulia
    Publication type:
    Article
    6

    The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents.

    Published in:
    Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1823, doi. 10.1007/s00262-021-03107-y
    By:
    • Zamora Atenza, Carlos;
    • Anguera, Geòrgia;
    • Riudavets Melià, Mariona;
    • Alserawan De Lamo, Letícia;
    • Sullivan, Ivana;
    • Barba Joaquin, Andrés;
    • Serra Lopez, Jorgina;
    • Ortiz, M. Angels;
    • Mulet, Maria;
    • Vidal, Sílvia;
    • Majem, Margarita
    Publication type:
    Article
    7

    Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents.

    Published in:
    Cancer Immunology, Immunotherapy, 2021, v. 70, n. 6, p. 1691, doi. 10.1007/s00262-020-02793-4
    By:
    • Zamora, Carlos;
    • Riudavets, Mariona;
    • Anguera, Georgia;
    • Alserawan, Letícia;
    • Sullivan, Ivana;
    • Barba, Andrés;
    • Serra, Jorgina;
    • Ortiz, M. Angels;
    • Gallardo, Pablo;
    • Perea, Lidia;
    • Gavira, Javier;
    • Barnadas, Agustí;
    • Majem, Margarita;
    • Vidal, Silvia
    Publication type:
    Article
    8

    Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study.

    Published in:
    Clinical & Translational Oncology, 2025, v. 27, n. 5, p. 2220, doi. 10.1007/s12094-024-03744-6
    By:
    • Vidal, Natalia;
    • Climent, Miguel Ángel;
    • Pérez, Sara;
    • Méndez-Vidal, María José;
    • Anguera, Georgia;
    • Martínez Salas, Imanol;
    • Gallardo, Enrique;
    • Cuéllar-Rivas, Miler Andrés;
    • Molina-Cerrillo, Javier;
    • Martín, Almudena;
    • Rodriguez-Vida, Alejo;
    • Almagro Casado, Elena;
    • Gonzalez, Macarena;
    • Domènech, Montserrat;
    • Martínez Kareaga, Mireia;
    • Fernández Calvo, Ovidio;
    • Villa Guzmán, José Carlos;
    • Vázquez Estévez, Sergio;
    • González-del-Alba, Aránzazu;
    • Puente, Javier
    Publication type:
    Article
    9
    10

    Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis.

    Published in:
    Clinical & Translational Oncology, 2024, v. 26, n. 7, p. 1798, doi. 10.1007/s12094-024-03393-9
    By:
    • Tapia, Jose C.;
    • Gavira, Javier;
    • Anguera, Georgia;
    • Sanchez, Sofia;
    • Romano, Alejandra;
    • Bosma, Freya;
    • Molina, Alejandra;
    • Sanz-Beltran, Judit;
    • Martin-Lorente, Cristina;
    • Algaba, Fernando;
    • Maroto, Pablo
    Publication type:
    Article
    11
    12
    13

    Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition.

    Published in:
    International Journal of Cancer, 2023, v. 153, n. 6, p. 1300, doi. 10.1002/ijc.34575
    By:
    • Roldán‐Romero, Juan M.;
    • Valdivia, Carlos;
    • Santos, Maria;
    • Lanillos, Javier;
    • Maroto, Pablo;
    • Anguera, Georgia;
    • Calsina, Bruna;
    • Martinez‐Montes, Angel;
    • Monteagudo, María;
    • Mellid, Sara;
    • Leandro‐García, Luis J.;
    • Montero‐Conde, Cristina;
    • Cascón, Alberto;
    • Roncador, Giovanna;
    • Coloma, Javier;
    • Robledo, Mercedes;
    • Rodriguez‐Antona, Cristina
    Publication type:
    Article
    14

    The influence of treatment sequence in the prognostic value of TMPRSS2‐ERG as biomarker of taxane resistance in castration‐resistant prostate cancer.

    Published in:
    International Journal of Cancer, 2019, v. 145, n. 7, p. 1970, doi. 10.1002/ijc.32238
    By:
    • Marín‐Aguilera, Mercedes;
    • Reig, Òscar;
    • Milà‐Guasch, Maria;
    • Font, Albert;
    • Domènech, Montserrat;
    • Rodríguez‐Vida, Alejo;
    • Carles, Joan;
    • Suárez, Cristina;
    • Alba, Aránzazu González;
    • Jiménez, Natalia;
    • Victoria, Iván;
    • Sala‐González, Núria;
    • Ribal, Maria José;
    • López, Sandra;
    • Etxaniz, Olatz;
    • Anguera, Geòrgia;
    • Maroto, Pablo;
    • Fernández, Pedro Luis;
    • Prat, Aleix;
    • Mellado, Begoña
    Publication type:
    Article
    15
    16
    17

    Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events.

    Published in:
    International Journal of Molecular Sciences, 2022, v. 23, n. 20, p. 12641, doi. 10.3390/ijms232012641
    By:
    • Alserawan, Leticia;
    • Anguera, Geòrgia;
    • Zamora Atenza, Carlos;
    • Serra López, Jorgina;
    • Martínez-Martínez, Laura;
    • Riudavets Melià, Mariona;
    • Sullivan, Ivana;
    • Barba Joaquin, Andrés;
    • Majem Tarruella, Margarita;
    • Vidal, Silvia
    Publication type:
    Article
    18

    Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents.

    Published in:
    Frontiers in Oncology, 2020, v. 10, p. N.PAG, doi. 10.3389/fonc.2020.01677
    By:
    • Riudavets, Mariona;
    • Mosquera, Joaquin;
    • Garcia-Campelo, Rosario;
    • Serra, Jorgina;
    • Anguera, Georgia;
    • Gallardo, Pablo;
    • Sullivan, Ivana;
    • Barba, Andrés;
    • del Carpio, Luís;
    • Barnadas, Agustí;
    • Gich, Ignasi;
    • Majem, Margarita
    Publication type:
    Article